Balasubramanyam Karanam to Antineoplastic Agents
This is a "connection" page, showing publications Balasubramanyam Karanam has written about Antineoplastic Agents.
Connection Strength
0.233
-
Anchoori RK, George L, Tseng SH, Lam B, Polkampally S, Amiano AD, Foran P, Tsingine H, Samanapally H, Carrizo Velasquez F, Das S, Xing D, Bin Salam A, Karanam B, Hung CF, Roden RBS. Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. PLoS One. 2021; 16(9):e0256937.
Score: 0.122
-
Bazzaro M, Anchoori RK, Mudiam MK, Issaenko O, Kumar S, Karanam B, Lin Z, Isaksson Vogel R, Gavioli R, Destro F, Ferretti V, Roden RB, Khan SR. a,?-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem. 2011 Jan 27; 54(2):449-56.
Score: 0.058
-
Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem. 2003 May 23; 278(21):19134-40.
Score: 0.034
-
Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One. 2015; 10(1):e116389.
Score: 0.019